

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the EPOLINE Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:44:00 ON 08 SEP 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:44:10 ON 08 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    7 SEP 2008    HIGHEST RN 1047406-12-1  
DICTIONARY FILE UPDATES:   7 SEP 2008    HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10596745s6.str



```

chain nodes :
1  2  3  4  6  7  9  10  12  13  14  15
chain bonds :
1-10  2-3  2-10  3-13  4-13  4-14  6-7  6-14  7-9  9-15  12-15
exact/norm bonds :
1-10  2-10  4-13  4-14  6-7  6-14  7-9  9-15  12-15
exact bonds :
2-3  3-13

```

G1:C,O,N

G2:C,O,N

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 6:CLASS 7:CLASS 9:CLASS 10:Atom 12:Atom
13:CLASS 14:CLASS 15:CLASS
Element Count :
Node 10: Limited
      C,C4
      N,N2

```

L1        STRUCTURE UPLOADED

```

=> s l1 sss sam
SAMPLE SEARCH INITIATED 10:44:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    15428 TO ITERATE

```

```

13.0% PROCESSED        2000 ITERATIONS                    3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE    **COMPLETE**
                         BATCH    **COMPLETE**


```

PROJECTED ITERATIONS: 301120 TO 316000  
PROJECTED ANSWERS: 174 TO 750

L2 3 SEA SSS SAM L1

=> d scan


L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(1-piperidinyl)phenyl]methyl]-  
MF C25 H26 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)-  
MF C17 H14 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Urea, N-[3-[2-(6-amino-3-pyridazinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]-  
MF C20 H20 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s c4n2/rf

L3 2537685 C4N2/RF

=> s l1 sub=l3 full

FULL SUBSET SEARCH INITIATED 10:45:27 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 26775 TO ITERATE

100.0% PROCESSED 26775 ITERATIONS

307 ANSWERS

SEARCH TIME: 00.00.01

L4 307 SEA SUB=L3 SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

183.97

184.18

FILE 'CAPLUS' ENTERED AT 10:45:36 ON 08 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2008 VOL 149 ISS 11

FILE LAST UPDATED: 7 Sep 2008 (20080907/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l4

L5 8 L4

=> d ibib abs hitstr 8

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:158661 CAPLUS

DOCUMENT NUMBER: 142:240460

TITLE: Preparation of pyrimidine derivatives as ErbB kinase inhibitors

INVENTOR(S): Reno, Michael John; Stevens, Kirk Lawrence; Waterson, Alex Gregory; Zhang, Yuemei

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005016914	A1	20050224	WO 2004-US26251	20040811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1654251	A1	20060510	EP 2004-781004	20040811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007502298	T	20070208	JP 2006-523388	20040811
US 20060205740	A1	20060914	US 2006-568052	20060210
PRIORITY APPLN. INFO.:			US 2003-495180P	P 20030814
			WO 2004-US26251	W 20040811
OTHER SOURCE(S):			CASREACT 142:240460; MARPAT 142:240460	
GI				



AB Title compds. I [wherein A = alkenylene, alkynylene; R = alkylene; R1 = -(Z)-(Z1)m-(Z2)n; Z = hetero/aryl, hetero/arylene; Z1 = CH2 where m = 0-1; Z2 = OH and derivs., halo, CN, CONH2 and derivs. or heterocyclyl, where n = 0-1, etc.; R2 = H, alkyl; R3 = -(Q)-(Q1)r-(Q2); Q = hetero/arylene; Q1 = O, where r = 0-1; Q2 = arylalkyl, hetero/aryl; and their salts, solvates, and physiol. functional derivs.] were prepared as ErbB kinase inhibitors for treating cancer. Thus, reacting 2-benzyl-N-(5-vinylpyrimidin-4-yl)-1H-benzimidazol-5-amine (preparation given) with Ph iodide gave pyrimidine II in 8%. I showed inhibitory activity vs. EGFR, ErbB-2, and ErbB-4 protein tyrosine kinases with a pIC50 ≥ 5.0. I are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.


IT 845657-86-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-90-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845658-10-8P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-[2-(4-morpholinyl)ethyl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidines as ErB kinase inhibitors)

RN 845657-86-5 CAPLUS

CN 4-Morpholineethanamine, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]- (CA INDEX NAME)





RN 845657-90-1 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-10-8 CAPLUS  
 CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 7

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:588667 CAPLUS

DOCUMENT NUMBER: 143:115556

TITLE: Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases

INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060969	A1	20050707	WO 2004-GB5332	20041220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1737462 A1 20070103 EP 2004-806134 20041220  
 EP 1737462 B1 20080730



R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1917880 A 20070221 CN 2004-80041936 20041220  
 JP 2007517006 T 20070628 JP 2006-546305 20041220  
 US 20080027076 A1 20080131 US 2006-596740 20060622  
 IN 2006MN00847 A 20070420 IN 2006-MN847 20060717

PRIORITY APPLN. INFO.:

GB 2003-30001 A 20031224  
 GB 2004-16850 A 20040729  
 WO 2004-GB5332 W 20041220

OTHER SOURCE(S): CASREACT 143:115556; MARPAT 143:115556  
 GI



AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, urea II was synthesized in 21% yield by condensation of the corresponding aniline with Ph thiadiazolylcarbamate in the presence of Et3N in THF under microwave irradiation. This urea showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 0.879  $\mu$ M and 5.557  $\mu$ M, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857287-13-9P, Phenyl [3-[(4,6-diaminopyrimidin-5-


yl)ethynyl]phenyl]carbamate 857287-53-7P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)


RN 857287-13-9 CAPLUS

CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 857287-53-7 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[4-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




IT 857287-02-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857287-04-8P, 2-Phenyl-N-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857287-05-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)urea 857287-06-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]urea 857287-07-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea 857287-08-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]urea 857287-09-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea 857287-10-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857287-11-7P, Phenyl [4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-14-0P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-15-1P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-16-2P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-17-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-18-4P, N-[3-[[[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-19-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-20-8P, N-[3-[[[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]ami

no]phenyl]acetamide 857287-21-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-22-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-23-1P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-24-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-25-3P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 857287-26-4P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(morpholin-4-yl)phenyl]urea 857287-27-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-methylpiperidin-4-yl)urea 857287-28-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-propylpiperidin-4-yl)urea 857287-29-7P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857287-30-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857287-31-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857287-32-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857287-35-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857287-36-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-37-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[5-tert-butylisoxazol-3-yl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-39-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-40-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-hydroxyethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-41-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-42-4P, N-[3-[[4-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-43-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-44-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2,4-dimethoxybenzyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-45-7P, N-[3-[[4-[[2-Aminoethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-46-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-47-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[4-(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-48-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[N-[2-(dimethylamino)ethyl]methylamino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-49-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(piperidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-50-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-51-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-52-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-57-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 857287-04-8 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-05-9 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 857287-06-0 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857287-07-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857287-08-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857287-09-3 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 857287-10-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-methoxyphenyl]- (CA INDEX NAME)




RN 857287-11-7 CAPLUS

CN Carbamic acid, [4-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 857287-14-0 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857287-15-1 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)




RN 857287-16-2 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 857287-17-3 CAPLUS

CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-(trifluoromethyl)-2-pyridinyl)- (CA INDEX NAME)



RN 857287-18-4 CAPLUS




CN Acetamide, N-[3-[[[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl)- (CA INDEX NAME)




RN 857287-19-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)









RN 857287-23-1 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 857287-24-2 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-25-3 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)




RN 857287-26-4 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 857287-27-5 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 857287-28-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 857287-29-7 CAPLUS

CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857287-30-0 CAPLUS


CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-31-1 CAPLUS  
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857287-32-2 CAPLUS  
 CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 857287-35-5 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-36-6 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-37-7 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-pyrrolidiny)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-38-8 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857287-39-9 CAPLUS  
 CN Urea, N-[3-[2-[4-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-40-2 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(2-

hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-41-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-42-4 CAPLUS

CN Urea, N-[3-[2-[4-[[4-aminobutyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-43-5 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-44-6 CAPLUS  
 CN Urea, N-[3-[2-[4-[[2,4-dimethoxyphenyl)methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-45-7 CAPLUS  
 CN Urea, N-[3-[2-[4-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-46-8 CAPLUS  
 CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-47-9 CAPLUS  
 CN Urea, N-[3-[2-[4-[[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-48-0 CAPLUS

CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)




RN 857287-49-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-piperidiny)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-50-4 CAPLUS


CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(4-morpholiny)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)




RN 857287-51-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-piperidiny)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)






RN 857287-52-6 CAPLUS  
 CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-57-1 CAPLUS  
 CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
12.34	196.52
SINCE FILE	TOTAL
ENTRY	SESSION
-1.60	-1.60

STN INTERNATIONAL LOGOFF AT 10:47:30 ON 08 SEP 2008